<i>TMEM25</i>Is a Candidate Biomarker Methylated and Down-Regulated in Colorectal Cancer

Hrašovec, Sonja; Hauptman, Nina; Glavač, Damjan; Jelenc, Franc; Ravnik‐Glavač, Metka

doi:10.1155/2013/427890

Cited by 49 publications

(39 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 TMEM119 has an important role in osteoblast differentiation by regulating the BMP2 pathway. 21, 22, 23, 24 However, the expression and roles of TMEM119 in bone cancer remain unclear.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Upregulation and biological function of transmembrane protein 119 in osteosarcoma

et al. 2017

View full text Add to dashboard Cite

Osteosarcoma is suggested to be caused by genetic and molecular alterations that disrupt osteoblast differentiation. Recent studies have reported that transmembrane protein 119 (TMEM119) contributes to osteoblast differentiation and bone development. However, the level of TMEM119 expression and its roles in osteosarcoma have not yet been elucidated. In the present study, TMEM119 mRNA and protein expression was found to be up-regulated in osteosarcoma compared with normal bone cyst tissues. The level of TMEM119 protein expression was strongly associated with tumor size, clinical stage, distant metastasis and overall survival time. Moreover, gene set enrichment analysis (GSEA) of the Gene Expression Omnibus (GEO) GSE42352 dataset revealed TMEM119 expression in osteosarcoma tissues to be positively correlated with cell cycle, apoptosis, metastasis and TGF-β signaling. We then knocked down TMEM119 expression in U2OS and MG63 cells using small interfering RNA, which revealed that downregulation of TMEM119 could inhibit the proliferation of osteosarcoma cells by inducing cell cycle arrest in G0/G1 phase and apoptosis. We also found that TMEM119 knockdown significantly inhibited cell migration and invasion, and decreased the expression of TGF-β pathway-related factors (BMP2, BMP7 and TGF-β). TGF-β application rescued the inhibitory effects of TMEM119 knockdown on osteosarcoma cell migration and invasion. Further in vitro experiments with a TGF-β inhibitor (SB431542) or BMP inhibitor (dorsomorphin) suggested that TMEM119 significantly promotes cell migration and invasion, partly through TGF-β/BMP signaling. In conclusion, our data support the notion that TMEM119 contributes to the proliferation, migration and invasion of osteosarcoma cells, and functions as an oncogene in osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 However, little is known regarding the association between TMEMs and osteosarcoma. TMEM119, a member of the transmembrane protein family and also known as osteoblast induction factor (Obif), is O -glycosylated at its N-terminal region.…”

Section: Introductionmentioning

confidence: 99%

Upregulation and biological function of transmembrane protein 119 in osteosarcoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In addition, methylation of the hMLH1, p16INK4A, APC, MGMT, sFRP1, GATA-5, sFRP4, sFRP5, GATA-4, B4GALT1 TFPI2, SOX17 and TMEM25 genes has been described in several studies [11][12][13][14][15][16][17] . These genes are hypermethylated and downregulated in CRC and thus may serve as excellent candidate biomarkers.…”

Section: Dna Methylationmentioning

confidence: 94%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) causes approximately 600000 deaths annually and is the third leading cause of cancer mortality worldwide. Despite significant advancements in treatment options, CRC patient survival is still poor owing to a lack of effective tools for early diagnosis and a limited capacity for optimal therapeutic decision making. Since there exists a need to find new biomarkers to improve diagnosis of CRC, the research on epigenetic biomarkers for molecular diagnostics encourages the translation of this field from the bench to clinical practice. Epigenetic alterations are thought to hold great promise as tumor biomarkers. In this review, we will primarily focus on recent advances in the study of epigenetic biomarkers for colorectal cancer and discuss epigenetic biomarkers, including DNA methylation, microRNA expression and histone modification, in cancer tissue, stool, plasma, serum, cell lines and xenografts. These studies have improved the chances that epigenetic biomarkers will find a place in the clinical practices of screening, early diagnosis, prognosis, therapy choice and recurrence surveillance for CRC patients. However, these studies have typically been small in size, and evaluation at a larger scale of well-controlled randomized clinical trials is the next step that is necessary to increase the quality of epigenetic biomarkers and ensure their widespread clinical use.

show abstract

“…Similar effects were then observed in ovarian cancer (9) and glioma cells (10). Differential regulation of other TMEM members could be also observed in many cancers, such as lymphomas (TMEM176) (11), colorectal cancer (TMEM25) (12), meningiomas (TMEM30B) (13), renal cell carcinoma (different TMEMs) (2,14–20), paragangliomas and pheochromocytomas (TMEM127) (21), suggesting that TMEM family is prominent group for further cancer research. However there are vast different characteristic and localization between the members of TMEMs.…”

Section: Transmembrane Protein Familymentioning

confidence: 99%

TMEM39A and Human Diseases: A Brief Review

et al. 2017

View full text Add to dashboard Cite

Transmembrane Protein 39A (TMEM39A) is a member of TMEM family. The understanding about this protein is still limited. The earlier studies indicated that TMEM39A was a key mediator of autoimmune disease. TMEM39A seems to be involved in systemic lupus erythematosus and multiple sclerosis in numerous of populations. All of these works stop at insufficient information by using gene functioning methods such as: Genome-wide association studies (GWASs) and/or follow-up study. It is the fact that the less understood of TMEM39A actually is the attraction to the scientist in near future. In this review the current knowledge about TMEM39A and its possible roles in cell biology, physiology and pathology will be described.

show abstract

TMEM25Is a Candidate Biomarker Methylated and Down-Regulated in Colorectal Cancer

Cited by 49 publications

References 37 publications

Upregulation and biological function of transmembrane protein 119 in osteosarcoma

Upregulation and biological function of transmembrane protein 119 in osteosarcoma

Advances in epigenetic biomarker research in colorectal cancer

TMEM39A and Human Diseases: A Brief Review

Contact Info

Product

Resources

About